Osaka, Japan, Japan · Est. 1781 · 47,000 employees
Takeda is a global biopharmaceutical company focused on developing treatments in oncology, gastroenterology, neuroscience, and rare diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 16 drugs with upcoming expirations
Pipeline
By Phase
34 drugs in development
By Therapeutic Area
top 6
R&D Momentum
86/100
Pipeline Velocity
61/100
Trial Completion Rate
85/100
Pipeline Concentration
16/100
Pipeline Freshness
70/100
Strategic Signals
Activity
Last 14 days
A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions
Clinical Outcome of Ixazomib (NINLARO®) Based Regimens in Chinese Patients With Multiple Myeloma Previously Receiving a Bortezomib/Carfilzomib-Based (re)Induction Regimen in Clinical Setting of Real World: An Open-Label, Single-Arm, Multicenter, Observation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy
A Phase 1, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled, 5-Way Crossover Study Evaluating the Abuse Potential of Soticlestat (TAK-935) in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System Depressant Experience
A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Subjects
An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.
Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants With Moderate or Mild Hepatic Impairment and Normal Hepatic Function
Gaucher Disease Outcome Survey (GOS)
Details
Company Overview
$55.0B
Mkt Cap
$32.0B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Actos — ACTOS
Application NDA021073
Actos — ACTOS
Application NDA021073
Uloric — ULORIC
Application NDA021856
Alunbrig — ALUNBRIG
Application NDA208772 (NDA)
Vyvanse — VYVANSE
Application NDA208510 (NDA)
Vyvanse — VYVANSE
Application NDA208510 (NDA)
Rozerem — ROZEREM
Application NDA021782
Resotran — MOTEGRITY
Application NDA210166 (NDA)
Uloric — ULORIC
Application NDA021856
Uloric — ULORIC
Application NDA021856
Iclusig — ICLUSIG
Application NDA203469 (NDA)
Livtencity — LIVTENCITY
Application NDA215596 (NDA)
Rozerem — ROZEREM
Application NDA021782
Exkivity — EXKIVITY
Application NDA215310 (NDA)
Elunate — FRUZAQLA
Application NDA217564 (NDA)
Entyvio — ENTYVIO
Application BLA761133 (BLA)
Uloric — ULORIC
Application NDA021856
Vyvanse — ARYNTA
Application NDA219847 (NDA)
Vyvanse — ARYNTA
Application NDA219847 (NDA)
Mimrylo — MIMRYLO
Application NDA220605 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)